An approximately 49 year old male patient on TYSABRI (300 mg, IV, QM) for Multiple Sclerosis from 28 Dec 2007 
to 05 Jul 2013 reported relapse (presumed MS relapse), right leg lost some of its capability (onset 2007), and JCV 
antibodies through the roof (onset 2013).  Treatment was not reported and the outcome for the event JCV 
antibodies through the roof is unknown.  The event of relapse (presumed MS relapse) is resolved.  The event of 
right leg lost some of its capability is ongoing.  Causality was not assessed and TYSABRI therapy was discontinued
because of high JCV antibodies.
Print Time: 07-JUN-2016 03:01 PM If a field is blank, there is no data for that field Page 353 of 549
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information